These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
374 related articles for article (PubMed ID: 30902478)
1. Impact of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children under 15 years old in Madrid, Spain, 2007 to 2016: The HERACLES clinical surveillance study. Picazo JJ; Ruiz-Contreras J; Casado-Flores J; Negreira S; Baquero-Artigao F; Hernández-Sampelayo T; Otheo E; Amo MD; Méndez C; Vaccine; 2019 Apr; 37(16):2200-2207. PubMed ID: 30902478 [TBL] [Abstract][Full Text] [Related]
2. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014. Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682 [TBL] [Abstract][Full Text] [Related]
3. Effect of the different 13-valent pneumococcal conjugate vaccination uptakes on the invasive pneumococcal disease in children: Analysis of a hospital-based and population-based surveillance study in Madrid, Spain, 2007-2015. Picazo J; Ruiz-Contreras J; Casado-Flores J; Negreira S; Baquero F; Hernández-Sampelayo T; Otheo E; Méndez C; PLoS One; 2017; 12(2):e0172222. PubMed ID: 28207888 [TBL] [Abstract][Full Text] [Related]
4. Impact of pneumococcal conjugate vaccine (PCV7 and PCV13) on pneumococcal invasive diseases in Italian children and insight into evolution of pneumococcal population structure. Camilli R; D'Ambrosio F; Del Grosso M; Pimentel de Araujo F; Caporali MG; Del Manso M; Gherardi G; D'Ancona F; Pantosti A; Vaccine; 2017 Aug; 35(35 Pt B):4587-4593. PubMed ID: 28716556 [TBL] [Abstract][Full Text] [Related]
5. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children. Ruiz-Contreras J; Picazo J; Casado-Flores J; Baquero-Artigao F; Hernández-Sampelayo T; Otheo E; Méndez C; Del Amo M; Balseiro C; Vaccine; 2017 Aug; 35(35 Pt B):4646-4651. PubMed ID: 28711388 [TBL] [Abstract][Full Text] [Related]
6. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec. De Wals P; Lefebvre B; Deceuninck G; Longtin J Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962 [TBL] [Abstract][Full Text] [Related]
7. Serotypes, antimicrobial susceptibility, and molecular epidemiology of invasive and non-invasive Streptococcus pneumoniae isolates in paediatric patients after the introduction of 13-valent conjugate vaccine in a nationwide surveillance study conducted in Japan in 2012-2014. Nakano S; Fujisawa T; Ito Y; Chang B; Suga S; Noguchi T; Yamamoto M; Matsumura Y; Nagao M; Takakura S; Ohnishi M; Ihara T; Ichiyama S Vaccine; 2016 Jan; 34(1):67-76. PubMed ID: 26602268 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018. Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872 [TBL] [Abstract][Full Text] [Related]
9. Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012. Farnham AC; Zimmerman CM; Papadouka V; Konty KJ; Zucker JR; Nattanmai GV; Jose S; Rosen JB JAMA Pediatr; 2015 Jul; 169(7):646-52. PubMed ID: 25938798 [TBL] [Abstract][Full Text] [Related]
10. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490 [TBL] [Abstract][Full Text] [Related]
11. Expansion of serotype coverage in the universal pediatric vaccination calendar: short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain. Picazo J; Ruiz-Contreras J; Casado-Flores J; Negreira S; García-de-Miguel MJ; Hernández-Sampelayo T; Otheo E; Méndez C; Clin Vaccine Immunol; 2013 Oct; 20(10):1524-30. PubMed ID: 23925887 [TBL] [Abstract][Full Text] [Related]
12. Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar. Picazo J; Ruiz-Contreras J; Casado-Flores J; Giangaspro E; Del Castillo F; Hernández-Sampelayo T; Otheo E; Balboa F; Ríos E; Méndez C; Clin Vaccine Immunol; 2011 Jan; 18(1):89-94. PubMed ID: 21047996 [TBL] [Abstract][Full Text] [Related]
13. Persistent Circulation of Vaccine Serotypes and Serotype Replacement After 5 Years of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine in the United Kingdom. Kandasamy R; Voysey M; Collins S; Berbers G; Robinson H; Noel I; Hughes H; Ndimah S; Gould K; Fry N; Sheppard C; Ladhani S; Snape MD; Hinds J; Pollard AJ J Infect Dis; 2020 Mar; 221(8):1361-1370. PubMed ID: 31004136 [TBL] [Abstract][Full Text] [Related]
14. The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage. Ciruela P; Izquierdo C; Broner S; Muñoz-Almagro C; Hernández S; Ardanuy C; Pallarés R; Domínguez A; Jané M; Vaccine; 2018 Nov; 36(50):7744-7752. PubMed ID: 30473132 [TBL] [Abstract][Full Text] [Related]
15. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine. Sharma D; Baughman W; Holst A; Thomas S; Jackson D; da Gloria Carvalho M; Beall B; Satola S; Jerris R; Jain S; Farley MM; Nuorti JP Pediatr Infect Dis J; 2013 Feb; 32(2):e45-53. PubMed ID: 23080290 [TBL] [Abstract][Full Text] [Related]
16. Serotypes and Clonal Composition of Streptococcus pneumoniae Isolates Causing IPD in Children and Adults in Catalonia before 2013 to 2015 and after 2017 to 2019 Systematic Introduction of PCV13. Redin A; Ciruela P; de Sevilla MF; Gomez-Bertomeu F; Gonzalez-Peris S; Benitez MA; Trujillo G; Diaz A; Jou E; Izquierdo C; Perez-Moreno MO; Moraga-Llop F; Olsina M; Vinado B; Sanfeliu E; Garcia A; Gonzalez-di Lauro S; Garcia-Garcia JJ; Dominguez A; Sa-Leao R; Muñoz-Almagro C; Microbiol Spectr; 2021 Dec; 9(3):e0115021. PubMed ID: 34878302 [TBL] [Abstract][Full Text] [Related]
17. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458 [TBL] [Abstract][Full Text] [Related]
18. Pneumococcal serotype evolution in Western Europe. Tin Tin Htar M; Christopoulou D; Schmitt HJ BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008 [TBL] [Abstract][Full Text] [Related]
19. Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study. Bertran M; D'Aeth JC; Abdullahi F; Eletu S; Andrews NJ; Ramsay ME; Litt DJ; Ladhani SN Lancet Infect Dis; 2024 May; 24(5):546-556. PubMed ID: 38310905 [TBL] [Abstract][Full Text] [Related]